128 related articles for article (PubMed ID: 38570263)
1. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
J Pediatr Surg; 2024 Mar; ():. PubMed ID: 38570263
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.
Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA
J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773
[TBL] [Abstract][Full Text] [Related]
3. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
[TBL] [Abstract][Full Text] [Related]
4. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
[TBL] [Abstract][Full Text] [Related]
5. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
[TBL] [Abstract][Full Text] [Related]
6. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
Cervantes-Gomez F; Stellrecht CM; Ayres ML; Keating MJ; Wierda WG; Gandhi V
Oncotarget; 2019 Apr; 10(29):2793-2809. PubMed ID: 31073371
[TBL] [Abstract][Full Text] [Related]
7. PIM Kinases in Multiple Myeloma.
Wu J; Chu E; Kang Y
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
[TBL] [Abstract][Full Text] [Related]
8. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
9. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
10. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
Brunen D; de Vries RC; Lieftink C; Beijersbergen RL; Bernards R
Mol Cancer Ther; 2018 Apr; 17(4):849-857. PubMed ID: 29440296
[TBL] [Abstract][Full Text] [Related]
11. 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity.
Rocha Gda G; Oliveira RR; Kaplan MA; Gattass CR
Eur J Pharmacol; 2014 Oct; 741():140-9. PubMed ID: 25111243
[TBL] [Abstract][Full Text] [Related]
12. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
13. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
15. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
16. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
Brunen D; García-Barchino MJ; Malani D; Jagalur Basheer N; Lieftink C; Beijersbergen RL; Murumägi A; Porkka K; Wolf M; Zwaan CM; Fornerod M; Kallioniemi O; Martínez-Climent JÁ; Bernards R
Oncotarget; 2016 Jun; 7(25):37407-37419. PubMed ID: 27270648
[TBL] [Abstract][Full Text] [Related]
18. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
19. AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes.
Park YK; Obiang-Obounou BW; Lee KB; Choi JS; Jang BC
J Cell Mol Med; 2018 Apr; 22(4):2488-2497. PubMed ID: 29441719
[TBL] [Abstract][Full Text] [Related]
20. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]